Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.53 |
| ▸ | QRFPR | Q96P65 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | NPY4R | P50391 | 4/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.45 |
| ▸ | NPY1R | P25929 | 3/20 | 0.45 |
| ▸ | NPY2R | P49146 | 1/20 | 0.45 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.44 |
| ▸ | CCKBR | P32239 | 1/20 | 0.43 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.42 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6046826 | 0.84 | NPY4R (0.61) | NPY4RNPY5RNPY1RNPY2RCTSG | |
| SCHEMBL6046817 | 0.84 | NPY4R (0.61) | NPY4RNPY5RNPY1RNPY2RCTSG | |
| SCHEMBL6552216 | 0.84 | NPY4R (0.61) | NPY4RNPY5RNPY1RNPY2RCTSG | |
| SCHEMBL29299827 | 0.84 | FOLH1 (0.62) | FOLH1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29300547 | 0.84 | FOLH1 (0.62) | FOLH1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29300546 | 0.84 | FOLH1 (0.62) | FOLH1QRFPRNPY4RNPY5RNPY1R | |
| SCHEMBL6046837 | 0.84 | NPY4R (0.48) | NPY4RNPY5RNPY1RNPY2RCTSG | |
| SCHEMBL29300471 | 0.83 | FOLH1 (0.65) | FOLH1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL6805280 | 0.82 | NPY4R (0.54) | NPY4RNPY5RNPY1RNPY2RCTSG | |
| SCHEMBL24363268 | 0.81 | FOLH1 (0.49) | FOLH1QRFPRNPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072755-A1 | TF antagonist | STENNICKE HENNING RALF (DK) | 2004-04-15 | — | — | US | disclosed |
| WO-2004007557-A2 | TF ANTAGONIST | NOVO NORDISK A/S (DK) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072755-A1 | TF antagonist | TFPI, TFPI2, F3 | FOLH1 1366/4885QRFPR 476/4885ALDH1A1 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.